JAK1 and neoplasm: In contrast, driver mutations that confer immune evasion, such as inactivating mutations in the MHC antigen presentation pathway (β2-microglobulin, TAP1, NLRC5) or of the interferon-γ signaling pathway (JAK1) showed a high intra-tumor heterogeneity and often parallel the evolution of multiple distinct immune evasion drivers in different parts of the same tumor.